Shanghai Pharma New Retail Summit Grandly Unveils Integrated Strategy and Ecosystem Vision

In his opening remarks, Li Yongzhong, Executive Director and Executive President of Shanghai Pharmaceuticals, stated that in the face of challenges such as changes in the external environment and financial pressure on the payment side, Shanghai Pharma Holdings achieved record-high operating performance with the strong support of its partners. In response toNew Retail, New Business Models, New Payment Methods"Three New" layout, Li Yongzhong emphasized,2025 Marks the Dual Inception Year for AI and New Retail at Shanghai Pharmaceuticals HoldingWe look forward to collaborating with more like-minded partners to seize opportunities in the out-of-hospital market, focusing on building a collaborative network for the new retail industry. By leveraging favorable policy tailwinds, we aim to fully explore the incremental potential of innovative payment solutions. Pooling resources from all sides and embracing technological transformation, we strive to create greater value in advancing Shanghai Pharmaceuticals’ integrated new retail strategy and fostering synergistic growth within the industry ecosystem.

At the conference, Li Zhigang, Retail Business Director of Shanghai Pharmaceuticals Holdings and Chairman of Shanghai Pharma Cloud Health, officially released"Shanghai Pharmaceuticals' New Retail Integration Strategy". He pointed out,Leveraging Shanghai Pharmaceuticals’ retail network, which covers nearly 1,500 stores, along with its mature supply chain system, will continue to elevate the strategic level of its new retail initiatives, accelerate layout with a focus on professional pharmacies adjacent to hospitals, and advance the construction of a large-scale retail system encompassing innovative drug portfolios and wholesale-retail synergy.

Meanwhile, Li Zhigang emphasized the distinctive advantages of Shanghai Pharma’s new retail segment.Clarified the goal of building a professional, integrated, one-stop, closed-loop new retail model for Shanghai Pharmaceuticals. Through the four major business segments—SPH Cloud Health, Huashi Pharmacy, SPH Hospital-Adjacent Store Network, and Magnesium Health—we achieve organic business synergy and build an SPH retail business system that is “patient-centric.” Meanwhile,Empowered by omnichannel digital intelligence, we comprehensively upgrade retail management and service systems from both enterprise management and customer service perspectives, strengthen the integration of in-hospital and out-of-hospital services and optimize supply chains, with a focus on developing professional scenarios such as Direct-to-Patient (DTP) pharmacies and specialty drug services.In the future, Shanghai Pharmaceuticals Retail will deepen the synergy between wholesale and retail operations through an integrated operational platform, creating an ecological closed loop that covers the entire life cycle and drives the high-quality development of the new pharmaceutical retail industry.

Shanghai Pharmaceuticals Cloud Health CEO Qian Ye centered onShanghai Pharmaceuticals Cloud Health's New Strategy, with a focus on elaborating the development segments of specialty pharmacies.As the flagship platform of Shanghai Pharmaceuticals’ retail specialty pharmacies, Shangyao Cloud Health is committed to professionalism and intelligence, with the vision of becoming a leader in the out-of-hospital market for innovative drugs.

Currently, China's innovative drug market has entered a period of rapid development. Shanghai Pharmaceuticals Cloud Health will continue to strengthen its commitment to its mission,Closely aligning with the “golden triangle” of pharmaceutical companies, doctors and patients, and payers to build a multi-dimensional ecosystem addressing new out-of-hospital care, new payment models, and new digital intelligence needs.Establish diversified channels both within and outside the hospital to achieve integrated development,Comprehensively Supporting the Implementation of Shanghai Pharmaceuticals Holding’s “Trinity” Solution for Its Ecosystem, focusing on quality improvement and efficiency enhancement, accelerating the accessibility and affordability of innovative drugs, and driving the development of new pharmaceutical retail to new heights of efficiency and value.